Cocrystal Pharma (NASDAQ:COCP) Shares Down 1.9% – Here’s Why

Cocrystal Pharma, Inc. (NASDAQ:COCP) fell 1.9% on Monday . The stock traded as low as $1.73 and last traded at $1.79. 23,123 shares changed hands during trading, an increase of 10% from the average session volume of 20,949 shares. The stock had previously closed at $1.83.

Wall Street Analyst Weigh In

Separately, HC Wainwright cut their target price on shares of Cocrystal Pharma from $10.00 to $7.00 and set a “buy” rating on the stock in a research note on Thursday, August 22nd.

Cocrystal Pharma Stock Performance

The firm has a 50 day moving average price of $1.79 and a 200-day moving average price of $1.92. The company has a market cap of $18.21 million, a P/E ratio of -1.03 and a beta of 1.42.

Cocrystal Pharma (NASDAQ:COCP) last posted its quarterly earnings data on Wednesday, August 14th. The company reported ($0.53) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by ($0.02). On average, sell-side analysts forecast that Cocrystal Pharma, Inc. will post -1.94 EPS for the current fiscal year.

Cocrystal Pharma Company Profile

Cocrystal Pharma, Inc, a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, norovirus, and respiratory virus infections.